HiberCell, Inc.
16 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma (NCT06234605) | HiberCell, Inc. | 2024-04-29 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948) | HiberCell, Inc. | 2022-02-23 |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) (NCT05159778) | HiberCell, Inc. | 2021-11-09 |
| Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma (NCT04995094) | HiberCell, Inc. | 2021-08-15 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778) | HiberCell, Inc. | 2021-06-08 |
| Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD (NCT03246685) | HiberCell, Inc. | 2017-11-08 |
Track HiberCell, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.